EP3049378A1 - Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit - Google Patents

Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit

Info

Publication number
EP3049378A1
EP3049378A1 EP14849233.3A EP14849233A EP3049378A1 EP 3049378 A1 EP3049378 A1 EP 3049378A1 EP 14849233 A EP14849233 A EP 14849233A EP 3049378 A1 EP3049378 A1 EP 3049378A1
Authority
EP
European Patent Office
Prior art keywords
compound
reaction mixture
reaction
fluoropropyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14849233.3A
Other languages
German (de)
French (fr)
Other versions
EP3049378A4 (en
EP3049378B1 (en
Inventor
Edmund C. Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Specgx LLC
Original Assignee
Mallinckrodt LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt LLC filed Critical Mallinckrodt LLC
Priority to PL14849233T priority Critical patent/PL3049378T3/en
Publication of EP3049378A1 publication Critical patent/EP3049378A1/en
Publication of EP3049378A4 publication Critical patent/EP3049378A4/en
Application granted granted Critical
Publication of EP3049378B1 publication Critical patent/EP3049378B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine

Definitions

  • the present invention relates to improved processes for the preparation of radioiodinated 3-fluoropropyl-nor-3-CIT.
  • radioiodinated 3-fluoropropyl-nor-3-CIT (i.e., compound I) is a diagnostic agent useful for diagnosing and monitoring movement disorders and dementia, and has specific use in the diagnosis and monitoring of Parkinson's disease.
  • 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT has the following structure:
  • This compound can be prepared from anhydroecgonine methyl ester using a six step process, which relies on the conversion of an arylstannane precursor to the 1-123 labeled compound.
  • a six step process is generally disclosed in, for example, Swahn, et al., Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol.
  • the present invention is directed to a process for preparation of compound (I) comprising the following reaction scheme:
  • the present invention is directed to a process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
  • R 1 is selected from the group consisting of halogen, ⁇ - ⁇ Si(CH 3 ) 3 , and ⁇ - ⁇ Sn(CH 3 ) 3 .
  • the present invention relates to the preparation of 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT using an arylsilane intermediate.
  • the process avoids the use of hexamethylditin, and has a reduced number of steps as compared to previously known processes for the preparation of radioiodinated 3- fluoropropyl-nor-3-CIT from anhydroecgonine methyl ester (compound 1-1).
  • the present invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3-fluoropropanal. The process avoids the use of the ozone depleting compound 3-fluoro-l-bromopropane.
  • the present invention provides a process for the preparation of compound (I) comprising the following reaction scheme:
  • the present invention is directed to a process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
  • R 1 is selected from the group consisting of halogen, ⁇ - ⁇ Si(CH 3 ) 3 , and ⁇ - ⁇ Sn(CH 3 ) 3 .
  • the present invention relates to the preparation of I- 123 radioiodinated 3-fluoropropyl-nor-3-CIT (compound I) using an arylsilane intermediate.
  • the process avoids the use of hexamethylditin, and reduces the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-3-CIT from anhydroecgonine methyl ester (compound 1-1).
  • Step A of the process involves or comprises the formation of an arylsilane precursor by reacting anhydroecogonine methyl ester (compound 1-1) with a halogen-substituted phenyltrimethylsilane in a Grignard addition reaction:
  • X is a halogen, and preferably is I or Br.
  • a Grignard reagent may be prepared by contacting the halogen- substituted phenyltrimethylsilane with magnesium in the presence of a solvent.
  • Suitable solvents for use in formation of the Grignard reagent include ethereal solvents, such as tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl methyl ether, diethyl ether, and the like.
  • the halogen-substituted phenyltrimethylsilane is typically present in the solvent in at a molar concentration of from about 0.2 M to about 1.0 M.
  • the reaction mixture may optionally further include or comprise a compound for initiating formation of the Grignard reagent.
  • Suitable compounds include an iodine crystal or ethylene dibromide.
  • the compound is preferably included in the reaction mixture in an amount sufficient to catalyze formation of the Grignard reagent.
  • the reaction may be conducted at a variety of temperatures, for example, from about 30°C to about 90°C, and preferably is conducted at reflux.
  • the reaction is allowed to proceed until substantially complete, and typically for at least 30 minutes, and more typically from about 30 minutes to about 180 minutes, or from about 45 minutes to about 180 minutes.
  • the Grignard reagent forming reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
  • the solution comprising the Grignard reagent is contacted with compound 1-1 to form an arylsilane precursor (compound 2-1).
  • the Grignard reagent is preferably present in the reaction mixture in an amount of from about 2.2 to about 2.4 equivalents relative to compound 1-1 (e.g., about a 2.2:1 to about a 2.4:1 molar equivalent).
  • an additional solvent may be added to the reaction mixture.
  • suitable solvents include methylene chloride, tetrahydrofuran, diethyl ether, 2-methyltrethydrofuran, tert-butyl methyl ether, and the like.
  • the solvent comprises methylene chloride and diethyl ether (e.g., diethyl ether added during preparation of the Grignard reagent) in a volume:volume ratio of about 1.2:1.
  • compound 1-1 is present in the reaction mixture in a concentration of from about 0.1 M to about 0.3 M, and preferably is at a concentration of 0.17 M.
  • the reaction may be conducted at a variety of temperatures, for example, from about -40°C to about -90°C, including from about -60°C to about - 85°C, and from about -75°C to about -80°C.
  • the reaction is conducted at a temperature of -78°C and allowed to warm to 0°C. The reaction is allowed to proceed until completed, typically for at least 20 minutes.
  • the temperature of the reaction mixture may be further lowered following reaction, for example, to a temperature of from about - 75°C to about -80°C, and preferably to a temperature of -78°C.
  • the reaction is quenched with an acid, such as trifluoroacetic acid.
  • the reaction mixture is allowed to warm following addition of compound 1-1, for example, to from about 0°C to about 22°C, and then cooled again to a temperature of from about -40°C to about -90°C, and preferably to a temperature of -78°C. Following this second cooling, the reaction may be quenched with an acid, such as trifluoroacetic acid to obtain the arylsilane precursor (compound 2-1). Typically, the acid is added to the reaction mixture in a 1:1 molar ratio with the Grignard reagent.
  • an acid such as trifluoroacetic acid
  • Compound 2-1 may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, filtration, ether extraction, rotary evaporation of solvent, chromatography, or combinations thereof.
  • Step B conversion of compound 2-1 to compound 3-1
  • Step B of the process involves or comprises demethylating the arylsilane precursor (compound 2-1) to form compound 3-1:
  • Suitable demethylation reagents include 1- chloroethylchloroformate, vinyl chloroformate, 2,2,2-triethylchloroformate, and the like.
  • the demethylation reagent is preferably present in the reaction mixture in an amount of from about 1 equivalent to about 10 equivalents, and more preferably in an amount of about 7 equivalents, relative to compound 2-1.
  • the reaction mixture may further include or comprise one or more aprotic solvent.
  • suitable aprotic solvents include 1,2- dichloroethane, ethyl acetate, toluene, chloroform, and combinations thereof.
  • the solvent is 1,2-dichloroethane or toluene.
  • the solvent may be present in the reaction mixture in an amount of from about 1 mL to about 100 mL per gram of compound 2-1, and preferably in an amount of about 20 mL per gram of compound 2-1.
  • the reaction mixture may optionally further include or comprise an inorganic base.
  • suitable inorganic bases include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and combinations thereof.
  • the reaction mixture typically comprises the inorganic base in a molar ratio of compound 2-1 to inorganic base of from about 1:1 to about 1:6.
  • the demethylation reaction may result in formation of a carbamate intermediate compound.
  • the mixture is typically concentrated and heated in methanol, to decompose the intermediate carbamate.
  • the reaction mixture may optionally further comprise one or more reagents to assist in the decomposition of the intermediate carbamate. Suitable reagents include combinations of zinc and acetic acid.
  • the demethylation reagent is 1- chloroethylchloroformate
  • the reaction mixture contains about 7 equivalents of 1-chloroethylchloroformate relative to compound 2-1.
  • the reaction mixture is heated to 80°C for 3 hours, followed by addition of N,N- diisopropylethylamine, and heating to 80°C for an additional 3 hours.
  • Compound 3-1 may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, filtration, chromatography, or combinations thereof.
  • Step C conversion of compound 3-1 to compound 4-1
  • Step C of the process involves or comprises the N-alkylation of compound 3-1 to form compound 4-1:
  • compound 3-1 is contacted with a suitable alkylating agent, such as 3-fluoro-l-bromopropane, 3-fluoro-l-iodopropane, or 3- fluoropropanal.
  • a suitable alkylating agent such as 3-fluoro-l-bromopropane, 3-fluoro-l-iodopropane, or 3- fluoropropanal.
  • the alkylating agent is 3-fluoropropanal.
  • 3-fluoropropanal is commercially available, or may be prepared by oxidation of 3- fluoropan-l-ol using Dess- Martin periodinane or trichloroisocyanuric acid and TEMPO (i.e., 2,2,6,6-tetramethyl-l-piperidinyloxy).
  • the reaction mixture will comprise from about 1 to about 3 equivalents of alkylating agent, relative to compound 3-1.
  • the reaction mixture may further comprise a solvent.
  • suitable solvents include ethyl acetate, 1,2-dichloroethane, acetonitrile, dichloromethane, chloroform, and combinations thereof.
  • the reaction mixture may include a reducing agent.
  • suitable reducing agents include sodium triacetoxyborohydride, sodium cyanoborohydride, and formic acid.
  • the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound 3-1.
  • Step D conversion of compound 4-1 to compound (I)
  • Step D of the process is a radioiododesilation reaction, in which the trimethylsilane moiety of compound 4-1 is replaced with 1-123 to form compound (I):
  • reaction mixture may further comprise a buffer, such as acetate.
  • Non-limiting examples of suitable solvents include methanol, acetic acid, trifluoroacetic acid, and acetic acid in ethanol.
  • Non-limiting examples of suitable oxidizing agents include Chloramine-T (i.e., (N-chloro-p-toluenesulfonamido)sodium), tert-butyl hypochlorite, peracetic acid, and combinations thereof.
  • the reaction mixture may comprise a reagent, such as silver tetrafluoroborate, which increases the electrophilicity of the 1-123 source.
  • the reaction mixture will comprise from about 0.6 to about 10 micrograms of compound 4-1 per mCi of 1-123 from the 1-123 source.
  • the reaction mixture may comprise, per mCi of 1-123, from about 0.6 to about 10 micrograms of compound 4-1, about 3 microliters of trifluoroacetic acid, about 1.5 microliters of Chloramine-T, and about 0.25 microliters of methanokacetic acid (99:1).
  • the reaction mixture comprises [ 123 l]Nal, chloramine-T, and trifluoroacetic acid.
  • the reaction mixture comprises [ 123 I]ICI and silver tetrafluoroborate.
  • the reaction mixture comprises [ 123 l]Nal and tert-butyl hypochlorite.
  • the reaction mixture comprises [ 123 l]Nal and peracetic acid in acetate buffer.
  • the reaction is typically conducted at a temperature of from about 21°C to about 25°C, and allowed to proceed for at least about 15 minutes, and typically from about 15 minutes to about 2 hours.
  • reaction may be quenched by addition of a base, such as N H 4 OH, and compound (I) may be isolated using any suitable technique known in the art, such as solvent evaporation, chromatography, and combinations thereof.
  • a base such as N H 4 OH
  • suitable reaction conditions for Step D are described in, for example, Musachio, et al., Appl. Radiat. Isoi, 1996, Vol. 47, No. 1, p. 79-81.
  • the present invention relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3- fluoropropanal.
  • the process advantageously avoids the use of the ozone depleting compound 3-fluoro-l-bromopropane.
  • R 1 is selected from the group consisting of halogen, ⁇ - ⁇ Si(CH 3 ) 3 , and ⁇ - ⁇ Sn(CH 3 ) 3 .
  • the halogen is I.
  • R 1 is I or ⁇ - ⁇ Si(CH 3 ) 3 .
  • 3-fluoropropanal is commercially available, or may be prepared by oxidation of 3-fluoropan-l-ol using Dess-Martin periodinane or trichloroisocyanuric acid and TEMPO (i.e., 2,2,6,6-tetramethyl-l-piperidinyloxy) according to the following reaction:
  • the reaction mixture may further comprise a solvent.
  • suitable solvents include ethyl acetate, 1,2-dichoroethane, acetonitrile, dichloromethane, chloroform, and combinations thereof.
  • R 1 is as defined above.
  • a reducing agent in the reaction mixture to facilitate reduction of the iminium intermediate compound 1-2 to compound (III).
  • suitable reducing agents include sodium triacetoxyborohydride, sodium cyanoborohydride, and formic acid.
  • the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound (II).
  • the reducing agent may be added to the reaction mixture prior to or subsequent to reaction of compound (II) with the 3-fluoropropanal.
  • the Grignard reagent was prepared as follows: The reaction was initiated by adding about 0.6 mL (4 mmol) of (4-bromophenyl)trimethylsilane to a suspension of magnesium (0.286 g, 12 mmol) and an iodine crystal in 7 mL of ether and heating at reflux in an oil bath. After the reaction initiated, the mixture was diluted with 7 mL of ether and the remaining 1.7 mL (8 mmol) of (4- bromophenyl)trimethylsilane was added. The mixture was then heated at reflux for 1.5 hr.
  • reaction was worked up by concentrating in vacuo, adding 2 mL of 1:1 waterxoncentrated ammonium hydroxide. The mixture was extracted with three 1 mL portions of dichloromethane. The combined organic layers of each extraction were dried over sodium sulfate. A sample of the organic extracts was analyzed by gas chromatography, which showed 80% compound 3-1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT from anhydroecgonine methyl ester. The invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3-fluoropropanal.

Description

PREPARATION OF RADIOIODINATED 3-FLUOROPROPYL-NOR-BETA-CIT
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority of U.S. provisional application number 61/882,039, filed September 25, 2013, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to improved processes for the preparation of radioiodinated 3-fluoropropyl-nor-3-CIT.
BACKGROUND OF THE INVENTION
[0003] 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT (i.e., compound I) is a diagnostic agent useful for diagnosing and monitoring movement disorders and dementia, and has specific use in the diagnosis and monitoring of Parkinson's disease. 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT has the following structure:
[0004] This compound can be prepared from anhydroecgonine methyl ester using a six step process, which relies on the conversion of an arylstannane precursor to the 1-123 labeled compound. Such a process is generally disclosed in, for example, Swahn, et al., Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol.
XXXVIII, No. 7, p. 675-685. See also U.S. Patent No. 6,447,747 (disclosing halogendestannylation reactions). The reaction scheme commonly used to prepare 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT is set forth below:
[0005] The preparation of the arylstannane precursor requires the use of the highly toxic tin reagent hexamethylditin. The safe use of hexamethylditin requires engineering controls and substantial personal protective equipment. There is thus a need for a process for the production of 1-123 radioiodinated 3- fluoropropyl-nor-3-CIT that does not require the use of hexamethylditin.
[0006] Additionally, previously known methods for the conversion of a nortropane to the corresponding N-(3-fluoropropyl) analogue relied on alkylations using 3-fluoro-l-bromopropane. See, e.g., Swahn, et al., Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol. XXXVIII, No. 7, p. 675-685. However, 3-fluoro-l-bromopropane is known to be an ozone depleting compound. There is thus a need for a process for the production of N-(3-fluoropropyl) analogs of nortropanes, and in particular 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT, that does not require the use of 3-fluoro-l-bromopropane. SUMMARY OF THE INVENTION
[0007] In one aspect, the present invention is directed to a process for preparation of compound (I) comprising the following reaction scheme:
STEP A
[0008] wherein X is a halogen and Me is methyl.
[0009] In another aspect, the present invention is directed to a process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
(III)
(II)
[0010] wherein R1 is selected from the group consisting of halogen, {- }Si(CH3)3, and {-}Sn(CH3)3.
[0011] Other aspects and features of the invention are detailed below.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The present invention relates to the preparation of 1-123 radioiodinated 3-fluoropropyl-nor-3-CIT using an arylsilane intermediate. The process avoids the use of hexamethylditin, and has a reduced number of steps as compared to previously known processes for the preparation of radioiodinated 3- fluoropropyl-nor-3-CIT from anhydroecgonine methyl ester (compound 1-1). The present invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3-fluoropropanal. The process avoids the use of the ozone depleting compound 3-fluoro-l-bromopropane.
[0013] Thus, in one aspect, the present invention provides a process for the preparation of compound (I) comprising the following reaction scheme:
Reaction Scheme 1:
STEP A
1-1 2-1
3-1
[0014] wherein X is a halogen, and Me is methyl.
[0015] In another aspect, the present invention is directed to a process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
(III)
(II)
[0016] wherein R1 is selected from the group consisting of halogen, {- }Si(CH3)3, and {-}Sn(CH3)3.
Preparation of Compound (I)
[0017] In one aspect, the present invention relates to the preparation of I- 123 radioiodinated 3-fluoropropyl-nor-3-CIT (compound I) using an arylsilane intermediate. Advantageously, the process avoids the use of hexamethylditin, and reduces the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-3-CIT from anhydroecgonine methyl ester (compound 1-1).
Step A: conversion of compound 1-1 to compound 2-1
[0018] Step A of the process involves or comprises the formation of an arylsilane precursor by reacting anhydroecogonine methyl ester (compound 1-1) with a halogen-substituted phenyltrimethylsilane in a Grignard addition reaction:
STEP A
1 -1 2-1
[0019] wherein X is a halogen, and preferably is I or Br.
(i) Formation of Grignard Reagent
[0020] A Grignard reagent may be prepared by contacting the halogen- substituted phenyltrimethylsilane with magnesium in the presence of a solvent. Suitable solvents for use in formation of the Grignard reagent include ethereal solvents, such as tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl methyl ether, diethyl ether, and the like. The halogen-substituted phenyltrimethylsilane is typically present in the solvent in at a molar concentration of from about 0.2 M to about 1.0 M.
[0021] The reaction mixture may optionally further include or comprise a compound for initiating formation of the Grignard reagent. Suitable compounds include an iodine crystal or ethylene dibromide. The compound is preferably included in the reaction mixture in an amount sufficient to catalyze formation of the Grignard reagent.
[0022] The reaction may be conducted at a variety of temperatures, for example, from about 30°C to about 90°C, and preferably is conducted at reflux. The reaction is allowed to proceed until substantially complete, and typically for at least 30 minutes, and more typically from about 30 minutes to about 180 minutes, or from about 45 minutes to about 180 minutes. In some embodiments, the Grignard reagent forming reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
(ii) Grignard addition reaction
[0023] The solution comprising the Grignard reagent is contacted with compound 1-1 to form an arylsilane precursor (compound 2-1). The Grignard reagent is preferably present in the reaction mixture in an amount of from about 2.2 to about 2.4 equivalents relative to compound 1-1 (e.g., about a 2.2:1 to about a 2.4:1 molar equivalent).
[0024] In some embodiments, an additional solvent may be added to the reaction mixture. Suitable solvents include methylene chloride, tetrahydrofuran, diethyl ether, 2-methyltrethydrofuran, tert-butyl methyl ether, and the like. In one embodiment, the solvent comprises methylene chloride and diethyl ether (e.g., diethyl ether added during preparation of the Grignard reagent) in a volume:volume ratio of about 1.2:1. Typically, compound 1-1 is present in the reaction mixture in a concentration of from about 0.1 M to about 0.3 M, and preferably is at a concentration of 0.17 M.
[0025] The reaction may be conducted at a variety of temperatures, for example, from about -40°C to about -90°C, including from about -60°C to about - 85°C, and from about -75°C to about -80°C. Preferably, the reaction is conducted at a temperature of -78°C and allowed to warm to 0°C. The reaction is allowed to proceed until completed, typically for at least 20 minutes.
[0026] In some embodiments, the temperature of the reaction mixture may be further lowered following reaction, for example, to a temperature of from about - 75°C to about -80°C, and preferably to a temperature of -78°C. Following this second cooling, the reaction is quenched with an acid, such as trifluoroacetic acid.
[0027] In other embodiments, the reaction mixture is allowed to warm following addition of compound 1-1, for example, to from about 0°C to about 22°C, and then cooled again to a temperature of from about -40°C to about -90°C, and preferably to a temperature of -78°C. Following this second cooling, the reaction may be quenched with an acid, such as trifluoroacetic acid to obtain the arylsilane precursor (compound 2-1). Typically, the acid is added to the reaction mixture in a 1:1 molar ratio with the Grignard reagent.
[0028] Compound 2-1 may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, filtration, ether extraction, rotary evaporation of solvent, chromatography, or combinations thereof.
Step B: conversion of compound 2-1 to compound 3-1
[0029] Step B of the process involves or comprises demethylating the arylsilane precursor (compound 2-1) to form compound 3-1:
[0030] Suitable demethylation reagents include 1- chloroethylchloroformate, vinyl chloroformate, 2,2,2-triethylchloroformate, and the like. The demethylation reagent is preferably present in the reaction mixture in an amount of from about 1 equivalent to about 10 equivalents, and more preferably in an amount of about 7 equivalents, relative to compound 2-1.
[0031] The reaction mixture may further include or comprise one or more aprotic solvent. Non-limiting examples of suitable aprotic solvents include 1,2- dichloroethane, ethyl acetate, toluene, chloroform, and combinations thereof. Preferably, the solvent is 1,2-dichloroethane or toluene. The solvent may be present in the reaction mixture in an amount of from about 1 mL to about 100 mL per gram of compound 2-1, and preferably in an amount of about 20 mL per gram of compound 2-1.
[0032] The reaction mixture may optionally further include or comprise an inorganic base. Non-limiting examples of suitable inorganic bases include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and combinations thereof. The reaction mixture typically comprises the inorganic base in a molar ratio of compound 2-1 to inorganic base of from about 1:1 to about 1:6.
[0033] The demethylation reaction may result in formation of a carbamate intermediate compound. Thus, following the demethylation reaction, the mixture is typically concentrated and heated in methanol, to decompose the intermediate carbamate. In some embodiments, the reaction mixture may optionally further comprise one or more reagents to assist in the decomposition of the intermediate carbamate. Suitable reagents include combinations of zinc and acetic acid.
[0034] The reaction may be conducted at a variety of temperatures, for example, from about 60°C to about 115°C, including from about 75°C to about 115°C, and preferably is conducted at about 80°C. The reaction is allowed to proceed typically for at least about 1 hour, and preferably proceeds for about 3 hours. [0035] In one embodiment, a base, such as Ν,Ν-diisopropylethylamine may be added to the reaction mixture after about 3 hours of reaction. The base is typically added in an amount of about 1 equivalent, relative to compound 2-1. The reaction mixture may then be reheated to a temperature of from about 60°C to about 115°C, including from about 75°C to about 115°C, and preferably about 80°C, and the reaction allowed to proceed for an additional 3 hours.
[0036] In one preferred embodiment, the demethylation reagent is 1- chloroethylchloroformate, and the reaction mixture contains about 7 equivalents of 1-chloroethylchloroformate relative to compound 2-1. Preferably, the reaction mixture is heated to 80°C for 3 hours, followed by addition of N,N- diisopropylethylamine, and heating to 80°C for an additional 3 hours.
[0037] Compound 3-1 may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, filtration, chromatography, or combinations thereof.
Step C: conversion of compound 3-1 to compound 4-1
[0038] Step C of the process involves or comprises the N-alkylation of compound 3-1 to form compound 4-1:
[0039] In this step, compound 3-1 is contacted with a suitable alkylating agent, such as 3-fluoro-l-bromopropane, 3-fluoro-l-iodopropane, or 3- fluoropropanal. In a preferred embodiment, the alkylating agent is 3-fluoropropanal. 3-fluoropropanal is commercially available, or may be prepared by oxidation of 3- fluoropan-l-ol using Dess- Martin periodinane or trichloroisocyanuric acid and TEMPO (i.e., 2,2,6,6-tetramethyl-l-piperidinyloxy). Typically, the reaction mixture will comprise from about 1 to about 3 equivalents of alkylating agent, relative to compound 3-1.
[0040] The reaction mixture may further comprise a solvent. Non-limiting examples of suitable solvents include ethyl acetate, 1,2-dichloroethane, acetonitrile, dichloromethane, chloroform, and combinations thereof.
[0041] When 3-fluoropropanal is the alkylating agent, the reaction mixture may include a reducing agent. Non-limiting examples of suitable reducing agents include sodium triacetoxyborohydride, sodium cyanoborohydride, and formic acid. Typically, the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound 3-1.
[0042] The reaction may be conducted at a variety of temperatures, for example, from about -20°C to about 50°C, and typically is conducted at about 20°C. The reaction is allowed to proceed until substantially complete, and typically for from about 15 minutes to about 24 hours, and preferably for about 2 hours. Reaction completion may be determined using any suitable technique, such as H PLC.
[0043] Compound 4-1 may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, solvent evaporation, filtration, chromatography, or combinations thereof.
Step D: conversion of compound 4-1 to compound (I)
[0044] Step D of the process is a radioiododesilation reaction, in which the trimethylsilane moiety of compound 4-1 is replaced with 1-123 to form compound (I):
[0045] This reaction takes place by the addition of 1-123, to a solution of compound 4-1 in a solvent optionally in the presence of an oxidizing agent. Optionally, the reaction mixture may further comprise a buffer, such as acetate.
[0046] Non-limiting examples of suitable solvents include methanol, acetic acid, trifluoroacetic acid, and acetic acid in ethanol.
[0047] Non-limiting examples of suitable sources of 1-123 include sodium iodide (i.e., [123l] Nal) and iodinemonochloride (i.e., [123I]ICI).
[0048] Non-limiting examples of suitable oxidizing agents include Chloramine-T (i.e., (N-chloro-p-toluenesulfonamido)sodium), tert-butyl hypochlorite, peracetic acid, and combinations thereof.
[0049] In some embodiments, instead of an oxidizing agent, the reaction mixture may comprise a reagent, such as silver tetrafluoroborate, which increases the electrophilicity of the 1-123 source.
[0050] Typically, the reaction mixture will comprise from about 0.6 to about 10 micrograms of compound 4-1 per mCi of 1-123 from the 1-123 source. In one particular embodiment, the reaction mixture may comprise, per mCi of 1-123, from about 0.6 to about 10 micrograms of compound 4-1, about 3 microliters of trifluoroacetic acid, about 1.5 microliters of Chloramine-T, and about 0.25 microliters of methanokacetic acid (99:1).
[0051] In one embodiment, the reaction mixture comprises [123l]Nal, chloramine-T, and trifluoroacetic acid. In another embodiment, the reaction mixture comprises [123I]ICI and silver tetrafluoroborate. In still another embodiment, the reaction mixture comprises [123l]Nal and tert-butyl hypochlorite. In another embodiment, the reaction mixture comprises [123l]Nal and peracetic acid in acetate buffer. [0052] The reaction is typically conducted at a temperature of from about 21°C to about 25°C, and allowed to proceed for at least about 15 minutes, and typically from about 15 minutes to about 2 hours.
[0053] The reaction may be quenched by addition of a base, such as N H4OH, and compound (I) may be isolated using any suitable technique known in the art, such as solvent evaporation, chromatography, and combinations thereof. Suitable reaction conditions for Step D are described in, for example, Musachio, et al., Appl. Radiat. Isoi, 1996, Vol. 47, No. 1, p. 79-81.
Preparation of Compound (III)
[0054] In another aspect, the present invention relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3- fluoropropanal. The process advantageously avoids the use of the ozone depleting compound 3-fluoro-l-bromopropane.
[0055] Thus, in one embodiment, there is provided a process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
(III)
(II) wherein R1 is selected from the group consisting of halogen, {-}Si(CH3)3, and {- }Sn(CH3)3. Preferably, the halogen is I. In preferred embodiments, R1 is I or {- }Si(CH3)3.
[0056] 3-fluoropropanal is commercially available, or may be prepared by oxidation of 3-fluoropan-l-ol using Dess-Martin periodinane or trichloroisocyanuric acid and TEMPO (i.e., 2,2,6,6-tetramethyl-l-piperidinyloxy) according to the following reaction:
Dess-Martin periodinane
[0057] The reaction mixture may further comprise a solvent. Non-limiting examples of suitable solvents include ethyl acetate, 1,2-dichoroethane, acetonitrile, dichloromethane, chloroform, and combinations thereof.
[0058] The conversion of compound (II) to compound (III) may result in formation of an iminium intermediate (compound 1-2):
1 -2
[0059] wherein R1 is as defined above.
[0060] Thus, in some embodiments, it may be desirable to include a reducing agent in the reaction mixture to facilitate reduction of the iminium intermediate compound 1-2 to compound (III). Non-limiting examples of suitable reducing agents include sodium triacetoxyborohydride, sodium cyanoborohydride, and formic acid. Typically, the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound (II). The reducing agent may be added to the reaction mixture prior to or subsequent to reaction of compound (II) with the 3-fluoropropanal.
[0061] Suitable reaction conditions are described a bove for Step C of Reaction Scheme 1. [0062] Compound (III) may be isolated from the reaction mixture using any suitable technique known in the art, including, for example, solvent evaporation, filtration, chromatography, or combinations thereof.
EXAMPLES
[0063] The following examples illustrate various iterations of the processes bed herein.
Example 1: Production of Compound 2-1
1-1 2-1
[0064] The Grignard reagent was prepared as follows: The reaction was initiated by adding about 0.6 mL (4 mmol) of (4-bromophenyl)trimethylsilane to a suspension of magnesium (0.286 g, 12 mmol) and an iodine crystal in 7 mL of ether and heating at reflux in an oil bath. After the reaction initiated, the mixture was diluted with 7 mL of ether and the remaining 1.7 mL (8 mmol) of (4- bromophenyl)trimethylsilane was added. The mixture was then heated at reflux for 1.5 hr.
[0065] After it had cooled to room temperature, the Grignard solution was added over 25 min to the solution of anhydroecgonine methyl ester (compound 1-1) (4.9 mmol) in dichloromethane (18 mL) cooled in a dry-ice/acetone bath (-78°C). The mixture was stirred for an additional 25 min in the bath. The bath was then removed and the mixture was stirred for another 25 min. [0066] The reaction was again cooled in the dry-acetone bath and 1.6 g (11 mmol) of trifluoroacetic acid in 4 mL of dichloromethane was added over 25 min. The mixture was allowed to warm to room temperature in the bath overnight.
[0067] The mixture was poured into a stirred mixture of a solution of 1:2 concentrated ammonium hydroxide:water (18 mL) and 18 mL of ethyl of ethyl acetate was added. An additional 4 mL of concentrated ammonium hydroxide was added to raise the pH to 10.0. The mixture was vacuum filtered through a 0.45 micron filter paper to remove a gel-like solid.
[0068] The layers were separated and the aqueous layer was extracted with two additional 18 mL portions of ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulfate.
[0069] The solution was decanted from the ethyl acetate and concentrated on a rotovap. The residue was dissolved in EtOAc and filtered through a plug of silica 1.2 cm deep and about 2 cm in diameter. The plug was flushed with 100 mL of EtOAc. The filtrate was concentrated to a liquid, ~ 1.6 g.
[0070] The liquid residue was dissolved in about 4 mL of hexane and purified on a flash column of 25 g of silica packed in hexane. The column was eluted as follows:
150 mL of 1% of EtOAc and 0.5% TEA in hexane
150 mL of 2% of EtOAc and 1% TEA in hexane
400 mL of 3% of EtOAc and 1.5% TEA in hexane
150 mL of 4% of EtOAc and 2% TEA in hexane
100 mL of 5% of EtOAc and 2.5% TEA in hexane
[0071] The column fractions of >98% purity were combined and concentrated give 0.38 g of compound 2-1.
Example 2: Demethylation of Compound 2-1
[0072] In a test tube, a 25 mg (0.065 mmol) portion of compound 2-1 was dissolved in toluene (0.5 ml). 1-chloroethyl chloroformate (50 microliters, 0.45 mmol) was added and the test tube was heated at 85°C. After 3 hrs N,N-diisopropyl- N-ethylamine (11 microliters, 0.065 mmol) was added to the test tube and the mixture was heated, with a timer set to turn off heating after 3 additional hours. The mixture was concentrated to a solid by rotovapping and the residue was dissolved in 0.6 mL of methanol. The solution was heated under reflux, heating block temperature 68°C, for 2 hours. The reaction was worked up by concentrating in vacuo, adding 2 mL of 1:1 waterxoncentrated ammonium hydroxide. The mixture was extracted with three 1 mL portions of dichloromethane. The combined organic layers of each extraction were dried over sodium sulfate. A sample of the organic extracts was analyzed by gas chromatography, which showed 80% compound 3-1.
Example 3: Preparation of N-(3-fluoropropyl) CIT
[0073] In a vial, 16 mg of 3-fluoropropanol was dissolved in 1.3 mL of dichloromethane. 1.3 mL of 0.3 M Dess-Martin periodane in dichloromethane was added. The mixture was stirred for 1 hr at room temperature. The mixture was diluted with 0.5 mL of EtOAc and filtered through a 0.45 micron syringe filter. The filtrate was chilled in a -30°C bath and was added to a solution of 25 mg of nor-CIT containing 0.17 g of sodium triacetoxyborohydride and cooled in a -30°C bath (the solution temperature was -21°C). After 2 hrs, a sample of the reaction was worked up and analyzed by gas chromatography, which showed 75% N-(3-fluoropropyl) CIT.
[0074] When introducing elements of the present invention or the preferred embodiment(s) thereof, the articles "a", "an", "the", and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including", and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.
[0075] As various changes could be made in the above compounds, products, and processes without departing from the scope of the invention, it is intended that all matter contained in the above-description shall be interpreted as illustrative and not in a limiting sense.

Claims

WHAT IS CLAIMED IS:
1. A process for the preparation of compound (I) comprising the following reaction scheme:
STEP A
wherein:
X is a halogen, and Me is methyl.
2. The process of claim 1, wherein (1) the Step A occurs at a
temperature of from about -40°C to about -90°C, (2) the process further comprises quenching the Step A reaction with trifluoroacetic acid, or (3) a combination thereof.
3. The process of claim 1, wherein the demethylation reagent is selected from the group consisting of 1-chloroethylchloroformate, vinyl chloroformate, and 2,2,2-triethylchloroformate.
4. The process of claim 1, wherein the alkylating agent is selected from the group consisting of 3-fluoro-l-bromopropane, 3-fluoro-l-iodopropane, and 3- fluoropropanal.
5. The process of claim 4, wherein the reaction mixture of Step C further comprises a reducing agent selected from the group consisting of sodium
triacetoxyborohydride, sodium cyanoborohydride, and formic acid.
6. The process of claim 5, wherein the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound 3-1.
7. The process of claim 1, wherein the reaction mixture of Step D comprises a source of 1-123 selected from the group consisting of sodium iodide and iodinemonochloride.
8. The process of claim 1, wherein the reaction mixture of Step D comprises an oxidizing agent selected from the group consisting of Chloramine-T, tert-butyl hypochlorite, peracetic acid, and combinations thereof.
9. The process of claim 1, wherein the reaction mixture of Step D comprises iodinemonochloride and silver tetrafluoroborate.
10. A process for the preparation of a N-(3-fluoropropyl) compound (III), the process comprising contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III):
(III)
(II) wherein R1 is selected from the group consisting of halogen, {-}Si(CH3)3, and {-
}Sn(CH3)3
11. The process of claim 10, wherein R1 is {-}Si(CH3)3.
12. The process of claim 10, wherein the reaction is conducted in the presence of a reducing agent.
13. The process of claim 12, wherein the reducing agent is selected from the group consisting of sodium triacetoxyborohydride, sodium cyanoborohydride, and formic acid.
14. The process of claim 12, wherein the reducing agent is present in the reaction mixture in an amount of from about 2 equivalents to about 15 equivalents, relative to compound (II).
15. The process of any one of the preceding claims, wherein the halogen is Br or I.
EP14849233.3A 2013-09-25 2014-09-25 Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit Active EP3049378B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL14849233T PL3049378T3 (en) 2013-09-25 2014-09-25 Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882039P 2013-09-25 2013-09-25
PCT/US2014/057404 WO2015048250A1 (en) 2013-09-25 2014-09-25 Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit

Publications (3)

Publication Number Publication Date
EP3049378A1 true EP3049378A1 (en) 2016-08-03
EP3049378A4 EP3049378A4 (en) 2017-04-19
EP3049378B1 EP3049378B1 (en) 2018-12-05

Family

ID=52691501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14849233.3A Active EP3049378B1 (en) 2013-09-25 2014-09-25 Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit

Country Status (11)

Country Link
US (1) US9339565B2 (en)
EP (1) EP3049378B1 (en)
JP (2) JP6224256B2 (en)
AU (1) AU2014326601B2 (en)
BR (1) BR112016006129A2 (en)
CA (1) CA2922723C (en)
ES (1) ES2711122T3 (en)
MX (1) MX2016003035A (en)
PL (1) PL3049378T3 (en)
TR (1) TR201901758T4 (en)
WO (1) WO2015048250A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2569229T3 (en) 2010-05-12 2017-01-31 Nestec Sa Capsule, system and method for preparing a beverage by centrifugation.
US9513907B2 (en) * 2013-08-06 2016-12-06 Intel Corporation Methods, apparatus, instructions and logic to provide vector population count functionality
EP3718569B1 (en) 2015-05-22 2023-05-03 Translational Drug Development, LLC Benzamide and active compound compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190601A (en) * 1978-05-31 1980-02-26 Union Carbide Corporation Production of tertiary amines by reductive alkylation
US6123917A (en) * 1990-08-09 2000-09-26 Research Triangle Institute Method for making cocaine receptor binding ligands and intermediates therefor
US5698179A (en) * 1992-02-25 1997-12-16 Neuro Imaging Technologies, Llc Iodinated neuroprobe for mapping monoamine reuptake sites
US6447747B1 (en) 1996-10-29 2002-09-10 Guilford Pharmaceuticals Inc. Process for the preparation of radiopharmaceuticals
FI104048B (en) * 1997-06-16 1999-11-15 Map Medical Technologies Oy Process for the preparation of radioiodinated receptor substances for in vivo use
CA2721484A1 (en) 1999-05-12 2000-11-12 President And Fellows Of Harvard College Dopamine transporter imaging agents
JP2001213881A (en) * 2000-02-02 2001-08-07 Nihon Medi Physics Co Ltd Process for synthesis of anhydroecgonine derivative
BRPI0414862A (en) * 2003-10-03 2006-11-28 Pfizer imidazopyridine-substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
KR100789847B1 (en) * 2004-12-15 2007-12-28 (주)퓨쳐켐 A Preparation Method of Organo Fluoro Compounds in Alcohol Solvents
RU2474435C2 (en) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Stabilisation of radiopharmaceutical compositions
EP2398808B1 (en) * 2009-02-17 2013-11-20 Mallinckrodt LLC Process for the reductive alkylation of normorphinans
GB0922023D0 (en) * 2009-12-17 2010-02-03 Ge Healthcare Ltd Preparation of n-monofluoroalkyl compounds

Also Published As

Publication number Publication date
JP6423936B2 (en) 2018-11-14
WO2015048250A1 (en) 2015-04-02
BR112016006129A2 (en) 2017-08-01
US20150087838A1 (en) 2015-03-26
TR201901758T4 (en) 2019-03-21
AU2014326601B2 (en) 2018-01-18
CA2922723A1 (en) 2015-04-02
AU2014326601A1 (en) 2016-03-17
EP3049378A4 (en) 2017-04-19
PL3049378T3 (en) 2019-06-28
JP2016533390A (en) 2016-10-27
US9339565B2 (en) 2016-05-17
ES2711122T3 (en) 2019-04-30
JP6224256B2 (en) 2017-11-01
CA2922723C (en) 2022-04-19
EP3049378B1 (en) 2018-12-05
MX2016003035A (en) 2016-06-10
JP2017218460A (en) 2017-12-14

Similar Documents

Publication Publication Date Title
EP1161434B1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
JP4500454B2 (en) 1,4-diazabicyclo [3.2.2] nonane-4-carboxylate and carboxamide derivatives, their preparation and use in therapy
JP6423936B2 (en) Preparation of radioiodine labeled 3-fluoropropyl-NOR-β-CIT
EP0905135B1 (en) Cocaine receptor binding ligands
US7217822B2 (en) Process for making cabergoline
CA2658165A1 (en) Process for the preparation of tiotropium bromide
JP2012509351A5 (en)
JP3173602B2 (en) Novel intermediate for the production of enyne derivatives and its production method
HRP20050893A2 (en) Process for the preparation of a cyano-isobenzofuran
CN112876461A (en) Process for the preparation of nicotine and intermediates therefor
CN101805339B (en) Entecavir compound preparation method
CN104418855A (en) Improved method for preparing paliperidone and intermediates of paliperidone
JP5452165B2 (en) Process for producing quinuclidine
WO2013050929A1 (en) Manufacturing process for tiotropium bromide
JP4480802B2 (en) Brominating agent
US10059704B2 (en) 1,4-disubstituted 1,2,3-triazoles, methods for preparing same, and diagnostic and therapeutic uses thereof
FR2555580A1 (en) NOVEL AZABICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
KR102399991B1 (en) Methods and systems for camptothecin analog synthesis
JPS5980681A (en) Manufacture of vincamine derivative
ITMI961918A1 (en) PROCEDURE FOR THE PREPARATION OF CEPHALOSPORANIC DERIVATIVES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170317

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 451/02 20060101ALI20170313BHEP

Ipc: C07B 59/00 20060101AFI20170313BHEP

Ipc: C07F 7/08 20060101ALI20170313BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SPECGX, LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SPECGX LLC

INTG Intention to grant announced

Effective date: 20180626

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1072854

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014037580

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181205

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1072854

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181205

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190305

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190305

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2711122

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190306

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190405

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190405

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014037580

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

26N No opposition filed

Effective date: 20190906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190925

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190925

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230921

Year of fee payment: 10

Ref country code: GB

Payment date: 20230927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230831

Year of fee payment: 10

Ref country code: FR

Payment date: 20230925

Year of fee payment: 10

Ref country code: DE

Payment date: 20230927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231002

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231013

Year of fee payment: 10